This hospital has conducted a unique and innovative procedure using robotics. Photo via hcahoustonhealthcare.com

HCA Houston Healthcare Clear Lake performed its first peripheral lung biopsy using robotic-assisted technology this month, making it the first hospital in the area to perform the minimally-invasive and innovative procedure.

Pulmonologist Dr. Alfred Maksoud performed the first two robotically-assisted procedures on March 1 and was attended by thoracic surgeon Dr. Melissa Korb and pulmonologist Dr. Maher Dahdel.

The procedures were conducted via an ultra-thin, easily maneuverable catheter that's able to navigate tight airways and pass through tight bends. A three-dimensional module of the patient's lung (created prior to surgery through a CT scan) was displayed on a computer screen to serve as a reference point for the doctors, as well as a live camera footage inside the lung.

The technology allows doctors to now reach nodules in any airway segment in the lung and extract more precise biopsies from the peripheral lung areas.

It will make the treatment easier on patients, which traditionally would require a CT scan and needle inserted into the patient's chest wall from outside of the body to reach these abnormal spots. This presented high risks of lung collapses for those with advanced lung disease.

“The technology allows us to go through the natural airways of the lung, so there is no puncturing of the lung tissue from the outside of the lining of the lung,” Maksoud said in a statement. “It is a safer way to approach lesions that are in the periphery of the lung for patients who have fairly advanced underlying lung disease.”

Additionally, this technology will support early diagnosis of lung disease when used for screenings due to its ability to reach previously unreachable areas of the lung.

“Approximately 75 percent of lung cancer cases are diagnosed in an advanced stage. Early lung cancer detection is imperative to increase the survival rate,” Todd Caliva, CEO at HCA Houston Healthcare Clear Lake, said in a statement. “We're excited to implement new innovations that allow us to enhance the level of care our patients receive.”

Houston-area hospitals have become hubs for robotic-assisted surgery in recent years.

Baylor St. Luke's has become a top cardiac robotics program since 2019. Meanwhile, others, like Houston Methodist, have developed AI technologies to simulate entire surgeries artificially with a goal of allowing surgeons to practice and plan their technique.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.